Veracyte to Present at Upcoming Investor Conferences

Rhea-AI Summary

Veracyte (Nasdaq: VCYT), a leading global genomic diagnostics company, announced participation in two virtual investor conferences. The events include a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, 2021, at 9:40 AM ET and a presentation at the Raymond James Human Health Innovation Conference on June 23, 2021, at 2:40 AM ET. Live webcasts will be accessible on Veracyte's website, with replays available for 90 days post-event. Veracyte aims to enhance patient care through advanced genomic testing across various cancers and diseases.

Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced that Marc Stapley, chief executive officer, and Bonnie Anderson, executive chairwoman, are scheduled to participate in two upcoming virtual investor conferences:

• Goldman Sachs 42nd Annual Global Healthcare Conference
  Fireside chat on Wednesday, June 9, 2021, at 9:40 a.m. Eastern Time

• Raymond James Human Health Innovation Conference
  Presentation on Wednesday, June 23, 2021, at 2:40 a.m. Eastern Time

Live audio webcasts of the company’s presentations will be available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations. Replays of the webcasts will be available for 90 days following the conclusion of each live presentation broadcast.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping and renal cancer tests are in development. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005933/en/

FAQ

What dates will Veracyte participate in investor conferences?

Veracyte will participate in the Goldman Sachs conference on June 9, 2021, and the Raymond James conference on June 23, 2021.

What time is Veracyte's presentation at the Goldman Sachs conference?

Veracyte's fireside chat at the Goldman Sachs conference is scheduled for 9:40 AM Eastern Time.

How can I access the webcasts of Veracyte's presentations?

Live audio webcasts of Veracyte's presentations will be available on their website, with replays for 90 days afterward.

What is the focus of Veracyte's genomic tests?

Veracyte's genomic tests focus on improving patient care by aiding diagnosis and treatment decisions for various cancers and diseases.

What is the stock symbol for Veracyte?

Veracyte's stock symbol is VCYT.